Search Results 41-50 of 15928 for Emicizumab

1. A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES) - Mayo Clinic

   The purpose of this study is to evaluate the effectiveness of depemokimab 200 mg subcutaneous (SC) given every 6 months versus placebo in participants with ...

2. Hemophilia - Doctors and departments - Mayo Clinic

   Mayo Clinic researchers are examining the effectiveness of a variety of precautions taken to reduce the risk of hemophiliac hemorrhage during surgeries. Mayo ...

3. A Study to Evaluate the Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer - Mayo Clinic

   Pembrolizumab has been approved for treatment of patients with melanoma but has not been proven to be safe or helpful in patients with pancreatic cancer and is ...

4. A Study of Everolimus with or without Bevacizumab for Treating Patients with Advanced Kidney Cancer that Progressed after First-Line Therapy - Mayo Clinic

   Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can interfere ...

5. A Study to Evaluate the Addition of Immunotherapy into Adjuvant Therapy for Non-small Cell Lung Cancer - Mayo Clinic

   Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of ...

6. Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients with High-Risk Stage III-IV Melanoma that has been Removed by Surgery - Mayo Clinic

   Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor ...

7. Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis - Mayo Clinic

   The purpose of this study is to test the hypothesis that benralizumab will reduce exacerbation rates compared with placebo on top of standard-of-care therapy in ...

8. A Study Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma - Mayo Clinic

   PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and ...

9. Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma - Mayo Clinic

   Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...

10. A Study of Cemiplimab in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy - Mayo Clinic

    A Study of Cemiplimab in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, ...